The financing round drew participation from a syndicate of prominent healthcare investors, including Venrock Healthcare Capital Partners, General Atlantic, and Blackstone Multi-Asset Investing. These funds are earmarked for the advancement of AVR-001, an oral IL-23 receptor antagonist designed for once-weekly dosing in patients with inflammatory conditions such as psoriasis, ulcerative colitis, and Crohn’s disease.

This capital raise arrives as Avere prepares for a definitive merger with NextCure, Inc. The all-stock transaction, slated for completion in the second half of 2026, will result in a combined entity operating under the Avere Therapeutics name on the Nasdaq exchange under the ticker symbol AVRX. The current financing is expected to close immediately prior to the merger, providing the scale necessary to compete in the crowded therapeutic landscape for IL-23-driven diseases.